Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Wed, 26.10.2022
Coreo AG
H1 2022: Half-year figures in line with expectations; Lower new investments
forecast; Target price reduced to € 1.85 (previously: € 2.15); Rating: BUY
In the first six months of 2022, Coreo AG's earnings development was
largely in line with our expectations. This applies in particular to rental
income, which increased significantl [ … ]
Thu, 29.09.2022
Cogia AG
Focus on organic and dynamic growth. Global cooperations show international
demand for Cogia products.
Cogia AG is a provider of AI-based semantic solutions in the field of big
data analytics and media monitoring technology with a focus on customer
experience in very dynamic markets. The management plans strong organic and
inorganic growth. Due [ … ]
Thu, 29.09.2022
Cogia AG
Focus on organic and dynamic growth. Global cooperations show international
demand for Cogia products.
Cogia AG is a provider of AI-based semantic solutions in the field of big
data analytics and media monitoring technology with a focus on customer
experience in very dynamic markets. The management plans strong organic and
inorganic growth. Due [ … ]
Tue, 13.09.2022
HAEMATO AG
1st HY 2022: Declining sales and earnings development as expected due to
discontinuation of sales with corona rapid tests, earnings forecast
confirmed, price target reduced to EUR 37.55 (previously: EUR 49.00) after
increase of risk-free interest rate; rating: BUY
As expected, HAEMATO AG showed an overall decline in business development
in the f [ … ]
Tue, 13.09.2022
HAEMATO AG
1st HY 2022: Declining sales and earnings development as expected due to
discontinuation of sales with corona rapid tests, earnings forecast
confirmed, price target reduced to EUR 37.55 (previously: EUR 49.00) after
increase of risk-free interest rate; rating: BUY
As expected, HAEMATO AG showed an overall decline in business development
in the f [ … ]
Mon, 12.09.2022
EPTI AB
Adjustment of NAV due to market conditions; Still very high upside
potential; Very promising investment Apotekamo executes financing round and
significantly increases valuation; Target price SEK 9.16 / EUR 0.85;
Rating: Buy
In the first half of 2022, consolidated sales increased by 489.6% to SEK
101.46 million (PY: SEK 17.21 million). With its o [ … ]
Mon, 12.09.2022
EPTI AB
Adjustment of NAV due to market conditions; Still very high upside
potential; Very promising investment Apotekamo executes financing round and
significantly increases valuation; Target price SEK 9.16 / EUR 0.85;
Rating: Buy
In the first half of 2022, consolidated sales increased by 489.6% to SEK
101.46 million (PY: SEK 17.21 million). With its o [ … ]
Wed, 07.09.2022
Media and Games Invest SE
H1 2022: Continuation of dynamic revenue growth despite more challenging
market environment; solid financial performance through platform-based
business model; GBC estimates and target price maintained after
confirmation of corporate guidance
Business development in the HY1 2022
Media and Games (MGI) announced its half-year figures for the cur [ … ]
Wed, 07.09.2022
Media and Games Invest SE
H1 2022: Continuation of dynamic revenue growth despite more challenging
market environment; solid financial performance through platform-based
business model; GBC estimates and target price maintained after
confirmation of corporate guidance
Business development in the HY1 2022
Media and Games (MGI) announced its half-year figures for the cur [ … ]
Mon, 05.09.2022
Aspermont Limited
Record HY results 2022 - 65% Gross Profit Margin - Entering their 4th
growth phase
Continuing their fast growth rate. The company's long-term strategy
implemented a few years ago has delivered as promised. Revenues are up 28%
YoY, reaching $9.3M AUD.
Strong HY cash position. The company has over $6.6M cash on hand.
Highest HY gross margin. T [ … ]